Biogen (BIIB)
(Delayed Data from NSDQ)
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Zacks News
Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up
by Zacks Equity Research
Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.
Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed
by Zacks Equity Research
Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares.
Biogen (BIIB) Tops Q2 Earnings and Revenue
by Zacks Equity Research
Biogen (BIIB) reported better-than expected earnings in the second quarter of 2017 with revenue beating estimates.
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.
Top Stock Reports for Boeing, AbbVie & U.S. Bancorp
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), AbbVie (ABBV), and U.S. Bancorp (USB).
Better Days Ahead for the Pharma Sector?
by Arpita Dutt
Sales, R&D, strong results, and a higher number of FDA approvals.
Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why
by Zacks Equity Research
Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.
Bear of the Day: Bioverativ (BIVV)
by Kevin Cook
Biogen spin-off just reported its first quarter and made an acquisition, but estimates were trimmed
Biogen Loses Top Executive Again, CFO Clancy to Join Alexion
by Zacks Equity Research
Biogen Inc.'s (BIIB) chief financial officer (CFO) for the last 10 years, Paul Clancy, is joining Alexion Pharmaceuticals, Inc. (ALXN) next month.
Biogen/Ionis Spinraza Granted Marketing Authorization in EU
by Zacks Equity Research
Biogen Inc. (BIIB) announced granting of marketing authorization to its marketed drug Spinraza (nusinersen) by European Commission under the accelerated assessment program for treating patients with 5q spinal muscular atrophy.
5 Drug Stocks in Focus on World MS Day
by Arpita Dutt
Life with MS -- this world MS day, here's a look at 5 stocks including Biogen (BIIB) that are key players in the multiple sclerosis (MS) market.
The Zacks Analyst Blog Highlights: UnitedHealth Group, Union Pacific, Biogen, United Technologies and Accenture
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth Group, Union Pacific, Biogen, United Technologies and Accenture
Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017?
by Zacks Equity Research
On May 29, 2017, we issued an updated report on Nektar Therapeutics (NKTR).
Biotech Stock Roundup: Puma Soars on Advisory Panel Vote, Priority Review for Kite Drug
by Arpita Dutt
Key highlights in the biotech sector include a favorable advisory panel vote for Puma (PBYI) and positive data and positive data from companies like Inovio and BioCryst.
Top Research Reports for UnitedHealth Group, Union Pacific & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc (UNH), Union Pacific Corporation (UNP) and Biogen Inc (BIIB).
Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer
by Zacks Equity Research
Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.
Biogen (BIIB) Down 9.5% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
BIIB reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen's Fampyra Conditional Approval Converted to Standard
by Zacks Equity Research
Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal
by Arpita Dutt
Quite a few deals were announced this week including by companies like Biogen (BIIB).
Biogen (BIIB) Buys Stroke Candidate Cirara for $120M
by Zacks Equity Research
Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals' phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI).
The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson
What's in the Cards for Ionis (IONS) this Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report first-quarter 2017 results on May 9. Last quarter, the company recorded a positive earnings surprise of 265%. Let's see how things are shaping up for this announcement.
Top Research Reports for May 4, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), JPMorgan (JPM) and Union Pacific (UNP).
Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) reported loss of 25 cents per share in the first quarter of 2017 (including the impact of stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 16 cents.
Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down
by Zacks Equity Research
Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.